Feb 3, 2009|
Exports show signs of revival
China showing signs of recovery?
China's growth may have considerably slowed down in the last quarter impacted by the global economic meltdown. But the Chinese Premier has stated that he saw signs of recovery in the final days of 2008. Although, he believes that more stimulus measures will be needed. China has been hit hard by falling exports, waning demand, fears of social unrest as thousands of workers were forced to leave cities to move back to villages in the wake of factories closing down. China's economic growth slowed to 6.8% YoY in the last quarter of 2008, dragging down the annual rate of expansion to a seven-year low of 9% YoY.
Interestingly, China's stockmarkets have a different story to tell. After being relentlessly battered in 2008, which saw the Chinese indices plunge by a massive 65%, the Shanghai Composite index gained 9.3% in January, the most among the world's 10 biggest markets. This has compelled the world's largest money managers to be confident about the fact that China will avert a recession. However, according to Bloomberg, Chinese stocks are trading at less than a third of their peak valuations reached in January 2008. The central bank has lowered interest rates five times since September and the Chinese government has already announced US$ 584 bn stimulus plan. Infact, it is expected that the country will enjoy faster growth than the rest of the world in 2009 and 2010 too. While this is most likely to be true given that its developed peers have already slipped into recession, China still has a tough task ahead of it in terms of overcoming the slowdown in its economy fuelled by the global financial crisis.
Pharma fortunes in the December quarter
Most of the major pharma companies have announced their December quarter results and the scenario has not exactly been something to cheer about. Two features were notable during the quarter. One was the huge quantum of forex losses that companies with forex debt had to incur due to the sharp depreciation of the rupee against the dollar. The other was the slowdown in revenue growth from the US with the US FDA delaying product approvals. Some companies were also at the receiving end as there was no exclusivity period that they garnered during the quarter, which was present in the corresponding quarter in the previous year.
Growth in the domestic market was either above or in line with the industry growth rate. The European region also impacted revenues as difficult market conditions continued to persist. In Germany, while the AOK (the largest insurance company in the country) announced the results of the tenders for a variety of drugs, the process itself was mired in controversy with a legal suit now pending. Thus, uncertainty will continue to prevail in the German market till the time the court case gets resolved. All in all, it was not a very enthusing quarter for the pharma sector which is not proving to be as defensive a play as FMCG.
India's exports display some resilience
After being battered in the months of October and November 2008, India's exports showed some signs of recovery in December, as reported in a leading business daily. While exports during the month still declined, the same was restricted at 1%, while October and November had seen exports falling by 12% and 10% respectively. Sectors which contributed to the better performance in December were pharmaceuticals, engineering products and some agricultural commodities. However, textiles, gems and jewellery and chemicals continued to face rough weather.
Handicraft and handloom exports suffered the most with exports plunging by 64% in December. Imports, on the other hand, registered a 9% YoY growth during the month. While there was a sharp increase in the growth of non-oil imports, low global oil prices helped to cushion the blow as oil imports fell equally sharply. India's cumulative exports growth for the period April-December 2008 was US$ 132 bn, clocking a growth of 17%. Conditions in the global markets continue to deteriorate and with no respite being visible in terms of economic recovery in 2009, a robust growth in exports will be difficult. This means that the export target of US$ 200 bn aimed for FY09 will be hard to achieve.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 23, 2017
Nowhere was the darkness deeper than in the nation's capital. There, no light shone. No flicker of awareness...observation...learning...or reflection appeared.
Aug 22, 2017
It's surprising Warren Buffett hasn't warned investors about the expensive stock market? Let us know why.
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Aug 22, 2017
Today, we are attacked by one preposterous thing after another, each of them even more absurd than the last.
More Views on News
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 16, 2017
The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407